PL4045039T3 - Hamowanie ludzkiej integryny alfa-4beta-7 - Google Patents

Hamowanie ludzkiej integryny alfa-4beta-7

Info

Publication number
PL4045039T3
PL4045039T3 PL20875989.4T PL20875989T PL4045039T3 PL 4045039 T3 PL4045039 T3 PL 4045039T3 PL 20875989 T PL20875989 T PL 20875989T PL 4045039 T3 PL4045039 T3 PL 4045039T3
Authority
PL
Poland
Prior art keywords
4beta
inhibition
integrin alpha
human integrin
human
Prior art date
Application number
PL20875989.4T
Other languages
English (en)
Inventor
Matthew G. Bursavich
Dan CUI
James E. Dowling
Kristopher N. Hahn
Bryce A. Harrison
Fu-Yang Lin
Blaise S. LIPPA
Bruce N. Rogers
Dawn M. Troast
Cheng Zhong
Kyle D. Konze
Aleksey I. Gerasyuto
Byungchan Kim
Salma RAFI
Tyler DAY
Eugene Hickey
Evelyne HOUANG
Robert Zahler
Original Assignee
Morphic Therapeutic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic, Inc. filed Critical Morphic Therapeutic, Inc.
Publication of PL4045039T3 publication Critical patent/PL4045039T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
PL20875989.4T 2019-10-16 2020-10-16 Hamowanie ludzkiej integryny alfa-4beta-7 PL4045039T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
PCT/US2020/055986 WO2021076890A1 (en) 2019-10-16 2020-10-16 INHIBITING HUMAN INTEGRIN α4β7

Publications (1)

Publication Number Publication Date
PL4045039T3 true PL4045039T3 (pl) 2025-09-15

Family

ID=73198501

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20875989.4T PL4045039T3 (pl) 2019-10-16 2020-10-16 Hamowanie ludzkiej integryny alfa-4beta-7

Country Status (36)

Country Link
US (3) US20240174632A1 (pl)
EP (3) EP4045039B1 (pl)
JP (7) JP7437490B2 (pl)
KR (2) KR20220102669A (pl)
CN (3) CN115087444B (pl)
AR (1) AR120244A1 (pl)
AU (2) AU2020366435A1 (pl)
BR (1) BR112022007284A2 (pl)
CA (1) CA3154269A1 (pl)
CL (1) CL2022000959A1 (pl)
CO (1) CO2022005759A2 (pl)
CR (1) CR20220205A (pl)
CU (1) CU20220027A7 (pl)
DK (1) DK4045039T3 (pl)
DO (2) DOP2022000081A (pl)
EC (1) ECSP22038978A (pl)
ES (1) ES3035561T3 (pl)
FI (1) FI4045039T3 (pl)
HR (1) HRP20250749T1 (pl)
HU (1) HUE071814T2 (pl)
IL (2) IL319053A (pl)
LT (1) LT4045039T (pl)
MA (1) MA57399B1 (pl)
MD (1) MD4045039T2 (pl)
MX (1) MX2022004406A (pl)
PE (1) PE20221829A1 (pl)
PH (1) PH12022550886A1 (pl)
PL (1) PL4045039T3 (pl)
PT (1) PT4045039T (pl)
RS (1) RS66976B1 (pl)
SI (1) SI4045039T1 (pl)
TW (6) TWI775182B (pl)
UA (1) UA130059C2 (pl)
UY (1) UY38926A (pl)
WO (3) WO2021076902A1 (pl)
ZA (2) ZA202203872B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773573A4 (en) 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
US11866429B2 (en) 2019-10-16 2024-01-09 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
EP4045039B1 (en) * 2019-10-16 2025-04-23 Morphic Therapeutic, Inc. Inhibiting human integrin alpha4beta7
CN118591535A (zh) * 2021-12-27 2024-09-03 西藏海思科制药有限公司 一种丙酸衍生物及其在医药上的应用
EP4585587A1 (en) 2022-09-09 2025-07-16 Xizang Haisco Pharmaceutical Co., Ltd. Propionic acid derivative and use thereof in medicine
KR20250120367A (ko) 2022-12-22 2025-08-08 신테라, 인크. 알파4 베타7 인테그린 안타고니스트 및 이의 용도
IL322849A (en) * 2023-02-21 2025-10-01 C4X Discovery Ltd Macrocyclic alpha 4 integrin inhibitors in cell 7
WO2024249328A2 (en) 2023-05-26 2024-12-05 Adarx Pharmaceuticals, Inc. Sod1-modulating compositions and methods of use thereof
WO2025026955A1 (en) * 2023-07-28 2025-02-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2025176107A1 (zh) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 一种吡啶酮衍生物及其在医药上的应用
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
CN119504796A (zh) * 2024-11-20 2025-02-25 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT691953E (pt) 1993-03-31 2001-01-31 Searle & Co 1-amidinofenil pirrolidinonas piperidinonas azetidinonas inibidoras de agregacao de plaquetas
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
WO1998016547A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
CA2268270A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Heterocyclic derivatives as factor xa inhibitors
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
ES2221227T3 (es) 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000000481A1 (en) 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
CN100360499C (zh) * 1999-05-07 2008-01-09 得克萨斯生物技术公司 抑制整联蛋白与其受体结合的丙酸衍生物
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6469047B1 (en) 1999-09-24 2002-10-22 Genentech, Inc. Tyrosine derivatives
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
CZ2003459A3 (cs) * 2000-08-30 2003-09-17 Pharmacia Corporation GEM-substituované antagonisty integrinu alfa v beta 3
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
ATE512163T1 (de) 2002-02-25 2011-06-15 Elan Pharm Inc Verabreichung von mitteln zur behandlung von entzündungen
DK1784426T3 (da) 2004-09-03 2012-03-12 Genentech Inc Humaniserede anti-beta7-antagonister og anvendelser deraf
EP1863940B1 (en) 2005-03-03 2012-06-06 Seedlings Life Science Ventures, LLC. Method of risk management for patients undergoing natalizumab treatment
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
ATE496041T1 (de) 2005-06-09 2011-02-15 Ucb Pharma Sa 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
AR085826A1 (es) 2011-03-31 2013-10-30 Genentech Inc METODOS DE ADMINISTRACION DE ANTAGONISTAS DE INTEGRINA b7
JP6449161B2 (ja) 2012-10-05 2019-01-09 ジェネンテック， インコーポレイテッド 炎症性腸疾患の診断治療方法
AU2015235986B2 (en) 2014-03-27 2020-12-03 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CN105658641B (zh) 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
EP3224280A1 (en) * 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2016138207A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
TW201835078A (zh) * 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
EP3773573A4 (en) 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
ES3003232T3 (en) * 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
EP4045039B1 (en) 2019-10-16 2025-04-23 Morphic Therapeutic, Inc. Inhibiting human integrin alpha4beta7

Also Published As

Publication number Publication date
MA57399B1 (fr) 2025-06-30
TWI791304B (zh) 2023-02-01
KR20220102669A (ko) 2022-07-20
WO2022081983A1 (en) 2022-04-21
TW202244040A (zh) 2022-11-16
EP4045039A4 (en) 2023-12-13
TWI857592B (zh) 2024-10-01
ECSP22038978A (es) 2022-06-30
LT4045039T (lt) 2025-08-11
IL292296A (en) 2022-06-01
CN116783161A (zh) 2023-09-19
BR112022007284A2 (pt) 2022-07-05
TWI888065B (zh) 2025-06-21
JP2024116230A (ja) 2024-08-27
JP2024054293A (ja) 2024-04-16
AU2020366435A1 (en) 2022-04-21
JP2023036958A (ja) 2023-03-14
US11370773B1 (en) 2022-06-28
CN115087444B (zh) 2024-09-17
TWI840047B (zh) 2024-04-21
MX2022004406A (es) 2022-08-25
AR120244A1 (es) 2022-02-09
KR20230088376A (ko) 2023-06-19
JP7500785B2 (ja) 2024-06-17
HRP20250749T1 (hr) 2025-08-15
TWI802477B (zh) 2023-05-11
CN119192137A (zh) 2024-12-27
ES3035561T3 (en) 2025-09-04
EP4228634A1 (en) 2023-08-23
CO2022005759A2 (es) 2022-05-20
WO2021076890A1 (en) 2021-04-22
JP7437495B2 (ja) 2024-02-22
EP4045039B1 (en) 2025-04-23
TW202500558A (zh) 2025-01-01
IL292296B2 (en) 2025-07-01
TWI775182B (zh) 2022-08-21
PH12022550886A1 (en) 2023-05-03
EP4045039A1 (en) 2022-08-24
CU20220027A7 (es) 2022-12-12
TW202332675A (zh) 2023-08-16
TW202315868A (zh) 2023-04-16
EP4559525A2 (en) 2025-05-28
CL2022000959A1 (es) 2023-04-28
PE20221829A1 (es) 2022-11-29
SI4045039T1 (sl) 2025-07-31
HUE071814T2 (hu) 2025-09-28
CA3154269A1 (en) 2021-04-22
EP4559525A3 (en) 2025-08-20
WO2021076890A4 (en) 2021-06-10
JP2022548809A (ja) 2022-11-22
DOP2022000081A (es) 2022-07-31
ZA202303992B (en) 2024-06-26
MD4045039T2 (ro) 2025-11-30
JP7717202B2 (ja) 2025-08-01
US20240174632A1 (en) 2024-05-30
US11104661B1 (en) 2021-08-31
JP2023500437A (ja) 2023-01-06
UA130059C2 (uk) 2025-10-29
WO2021076902A1 (en) 2021-04-22
EP4228634A4 (en) 2024-12-18
JP2022542184A (ja) 2022-09-29
RS66976B1 (sr) 2025-07-31
IL319053A (en) 2025-04-01
CR20220205A (es) 2022-07-22
JP7702004B2 (ja) 2025-07-02
IL292296B1 (en) 2025-03-01
CN115087444A (zh) 2022-09-20
ZA202203872B (en) 2024-01-31
DOP2025000034A (es) 2025-04-08
JP7437490B2 (ja) 2024-02-22
UY38926A (es) 2021-05-31
JP2024054296A (ja) 2024-04-16
FI4045039T3 (fi) 2025-06-20
AU2021361031A1 (en) 2023-06-08
JP7209116B2 (ja) 2023-01-19
TW202500559A (zh) 2025-01-01
TW202222793A (zh) 2022-06-16
DK4045039T3 (da) 2025-06-30
TW202126624A (zh) 2021-07-16
PT4045039T (pt) 2025-07-02

Similar Documents

Publication Publication Date Title
PL4045039T3 (pl) Hamowanie ludzkiej integryny alfa-4beta-7
IL280782A (en) Inhibiting αv β6 integrin
IL285178A (en) Compounds and uses thereof
IL257203B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
HUE065695T2 (hu) Szövet életképesség mérése
EP4331480C0 (en) DETECTION OF TISSUE INJURY
IL277778B (en) Bcl6 inhibitors
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
EP3572400A4 (en) EZH2 INHIBITOR AND ITS USE
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
EP3324894A4 (en) LATERAL AND MEDIAL SWITCHING KNEE PROSTHESIS
IL281927A (en) Combination therapy for melanoma
IL287904A (en) Combination treatment of arthritic disease
EP3415524A4 (en) INHIBITOR OF α-SYNNUCLEINE EXPRESSION
IL284514A (en) Halo-allylamine compounds and use thereof
EP3592377A4 (en) TISSUE KALLICREIN DOSAGE FORMS 1
EP4041729C0 (en) Inhibitors of human immunodeficiency virus replication
HUE071053T2 (hu) Az alfa-V-béta-6 integrin gátlószerei
IL285765A (en) Therapeutic uses of dulaglutide
IL285119A (en) Use of spiropidion
IL281409A (en) Musk inhibition
EP3962486A4 (en) ESCAPEMENT OF USP36
EP3958749A4 (en) Skin closure devices
EP3996650C0 (en) BATHTUB
EP3936017A4 (en) Bathtub